ISSN 2330-717X

Successful MERS Vaccine In Mice May Hold Promise For COVID-19 Vaccine

By

Vaccine research to vanquish the horrendous and deadly viruses may occasionally hold positive surprises for scientists and their fans. A team of researchers at the University of Iowa and the University of Georgia, USA have developed a vaccine that fully protects mice against a lethal dose of MERS, a notorious, close cousin of SARS-COV2 that causes COVID-19. Surprisingly, they found that their MERS vaccine also holds promise for developing vaccines against other coronaviruses diseases, including COVID-19, which at present holds many nations including India to ransom.

 Use of PIV5, an innocuous virus

Their vaccine is a parainfluenza virus (PIV5) carrying the “spike” protein that MERS uses to infect cells. Researchers showed that all the vaccinated mice survived a lethal dose of the MERS coronavirus. mBio, the Journal of the American Society for Microbiology published the results of the study on April 7, 2020.

 “PIV5 is an excellent viral vector candidate for vaccine development; it is safe and infects a large number of mammals without being associated with any diseases, except kennel cough in dogs,” the researchers clarified.

The team led by Paul McCray at the UI Carver College of Medicine, and Biao He, at the University Of Georgia College Of Veterinary Medicine, tested a MERS vaccine candidate in mice engineered to be susceptible to the MERS coronavirus and found that just one, relatively low dose of the vaccine given to the mice intra-nasally (inhaled through the nose) was sufficient to protect fully all the treated mice from a lethal dose of MERS coronavirus.

“Our new study indicates that PIV5 may be a useful vaccine platform for emerging coronavirus diseases, including SARS-CoV-2, the virus causing the ongoing COVID-19 pandemic,” says McCray, UI professor of paediatrics in a press release from the University of Iowa Health Care.

Some questions and answers

“Can you comment on the way the vaccine may be applied to persons and advantages if any, for accepting the method?

“The idea is to use this as a topical mucosal vaccine, similar to how the influenza vaccine FluMist is delivered. It may be advantageous to immunize this way for a respiratory pathogen like SARS-CoV-2,” Professor Paul McCray responded to my e-mail query.

“How stable is the vaccine at different temperatures?”

“This is a very good question.  PIV5 is used in vaccines for kennel cough.  We know that kennel cough vaccines can be stored in refrigerators for over 1 year. At -80 degrees, we can keep PIV5 stable for over 5 years. Currently, we are investigating storage at room temperature,” he replied.

To the question on the effectiveness of the vaccine for different age groups, Professor McCray conceded that they have not tested PIV5 vaccine in humans yet. 

“We expect it to be effective in both young and old,” McCray added.

 “How long it may take for getting the vaccine ready for use?”

“We have made a PIV5-based COVID-19 vaccine. We are testing it in different animal species right now. Based on experience we have had with other PIV5-based vaccines such as a PIV5-based RSV vaccine, we expect that PIV5-COVID-19 will perform well in non-human primates. Dr. He’s group is working on preparing a GMP lot of PIV5-COVID-19 vaccine, which is required for testing in humans, by the end of summer,” McCray said.  

McCray noted that, “The overall goal is to test this vaccine in humans as soon as FDA approves. It is possible that if there is FDA approval a trial could happen by the fall of 2020.  An advantage of this vaccine strategy is that it is likely that a small dose is sufficient for protection. This could help simplify production issues”.

McCray confidently drew the expected time line. Regulatory agencies are also changing their rigid stands. It may fast-forward such projects.

Humanity quickly needs an effective drug and an efficacious vaccine against the COVID 19 virus. A recent review published by the Coalition for Epidemic Preparedness Innovations (CEPI) in journal Nature noted that the publication of the genetic sequence of the coronavirus that causes COVID-19 triggered  intense global R&D activity to develop a vaccine against the disease. The CEPI found that as of 8 April 2020, this vaccine field includes 115 vaccine candidates. Five of the most advanced among them have entered human trial.  

According to the CEPI, “the current response to the coronavirus disease 2019 (COVID-19) pandemic involves aggressive implementation of suppression strategies, such as case identification, quarantine and isolation, contact tracing, and social distancing. However, models developed by the Imperial College COVID-19 Response Team suggest that “transmission will quickly rebound if interventions are relaxed”. The coalition asserted that   the development of COVID-19 vaccines that can be used globally is a priority for ending the pandemic.

Dr. K S Parthasarathy

Dr. K S Parthasarathy

Dr. K S Parthasarathy is former Secretary, Atomic Energy Regulatory Board and a former Raja Ramanna Fellow in the Strategic Planning Group, Department of Atomic Energy, Mumbai. Dr. K S Parthasarathy may be contacted at [email protected]

2 thoughts on “Successful MERS Vaccine In Mice May Hold Promise For COVID-19 Vaccine

  • Avatar
    April 29, 2020 at 8:51 pm
    Permalink

    Thanks Dr. Parthasarathy for this info. Hadn’t heard of this before.
    An effective vaccine against Covid-19 is an urgent need. The use of a innocuous vector to produce the antigen in-vivo that will induce immunity seems to be what many scientists are working on.
    What is making news now is the ChAdOx1 vaccine for nCoV-19 that is currently being investigated for prophylaxis against SARS-CoV-2.2 The ChAdOx1 viral vector was developed at the University of Oxford and has been investigated as a potential vector for vaccines against another human coronavirus, Middle Eastern respiratory syndrome coronavirus (MERS-CoV).1,3 The ChAdOx1 nCoV-19 vaccine, produced in a partnership between The University of Oxford’s Jenner Institute and Italian pharmaceutical manufacturer Advent Srl, consists of an attenuated adenovirus capable of producing the spike (S) protein of SARS-CoV-2, allowing for the formation of endogenous antibodies against these proteins and, consequently, against SARS-CoV-2

    A phase I/II single-blinded, randomized, placebo-controlled trial to investigate the safety, efficacy, and immunogenicity of the vaccine began in March 2020 with an expected completion date of May 2021.
    *The trial is taking place in the UK, where the vaccine will be administered intramuscularly to healthy adult volunteers between the ages of 18 and 55*

    The lead scientist Sarah Gilbert is so confident of it that larges scale production has started in 7 places. 3 in UK, 2 in Italy, 1 in China and 1 in India.

    Reply
  • Dr K S Parthasarathy
    May 3, 2020 at 8:01 am
    Permalink

    Thank you Dr. Rajan,
    Additionally, the Oxford Researchers decided that they will not give licence to any mutinational so that they can make any profit out of this vaccine. This vaccine is likely to appear in hospitals first.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.